Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Stifel cuts Boston Scientific stock price target on EP data review
Stifel has lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $85 from $90, while maintaining a Buy rating, ahead of the company’s Q1 2026 earnings report. This adjustment is based on a review of monthly electrophysiology hospital-purchasing data, which suggests that Boston Scientific’s Q1 2026 US EP consensus revenues of approximately $587 million are achievable. This news comes amidst mixed analyst reactions to the company’s recent CHAMPION-AF trial results for its Watchman heart implant, which met primary endpoints but showed a slightly higher ischemic stroke rate, causing some investor concern despite reaffirmations of Buy ratings from other firms.